Breathtec to Participate in the 2nd Annual RAI$E on the WEST COAST Small-Cap Investing Conference in Vancouver, BC, September...
September 14 2018 - 7:00AM
Breathtec Biomedical Inc. (CSE: BTH) (CNSX: BTH)
(FRANKFURT: BTI) (OTCQB: BTHCF) (the “Company”) will
be presenting at the 2nd Annual RAI$E on the WEST COAST Small-Cap
Investing Conference in Vancouver, BC, September 14-15. We will be
in Meeting Area #18, meeting investors & brokers for
back-to-back meetings; investors & brokers can register online
here: www.westcoast2018.eventbrite.ca
About RAI$E on the WEST COAST Small-Cap
Investing Conference:
September 14-15 | Fairmont Hotel Vancouver |
Vancouver, BC. RAI$E on the WEST COAST is a two-day conference
connecting small-cap companies with funds, finance professionals
and investors for a FULL DAY of scheduled meetings on Friday and a
NETWORKING DAY of World Class Salmon Fishing on Saturday.
ABOUT BREATHTEC BIOMEDICAL INC. Breathtec
Biomedical, Inc. (“Breathtec”) was formed to propel innovative
research in the area of airborne analysis as a medical screening
tool. Our efforts are aimed at leading the development of
commercially viable methods for the early screening of certain
pathogens. Our primary avenue of investigation is focused on
innovation and advances in the field of specialized mass
spectrometry.
Breathtec also recently announced that it will
be opening a new drug development division and has signed a Letter
of Intent (“LOI”) to acquire 100% of the shares of Nash
Pharmaceuticals Inc. (“Nash Pharma”). Nash Pharma is a clinical
stage pharmaceutical development company focused on drug
repurposing in the areas of non–alcoholic steatohepatitis (NASH),
chronic kidney disease (CKD) and inflammatory bowel disease (IBD).
For more information, visit www.breathtecbiomedical.com.
CONTACT INFORMATION
Christopher J. Moreau CEOBreathtec Biomedical Inc.604.398.4175
ext
701info@breathtechbiomedical.cominvestors@breathtecbiomedical.comwww.breathtecbiomedical.com
CAUTIONARY DISCLAIMER STATEMENT: No Securities
Exchange has reviewed nor accepts responsibility for the adequacy
or accuracy of the content of this news release. This news release
contains forward-looking statements relating to product
development, licensing, commercialization and regulatory compliance
issues and other statements that are not historical facts.
Forward-looking statements are often identified by terms such as
“will”, “may”, “should”, “anticipate”, “expects” and similar
expressions. All statements other than statements of historical
fact, included in this release are forward-looking statements that
involve risks and uncertainties. There can be no assurance that
such statements will prove to be accurate and actual results and
future events could differ materially from those anticipated in
such statements. Important factors that could cause actual results
to differ materially from the Company’s expectations include the
failure to satisfy the conditions of the relevant securities
exchange(s) and other risks detailed from time to time in the
filings made by the Company with securities regulations. The reader
is cautioned that assumptions used in the preparation of any
forward-looking information may prove to be incorrect. Events or
circumstances may cause actual results to differ materially from
those predicted, as a result of numerous known and unknown risks,
uncertainties, and other factors, many of which are beyond the
control of the Company. The reader is cautioned not to place undue
reliance on any forward-looking information. Such information,
although considered reasonable by management at the time of
preparation, may prove to be incorrect and actual results may
differ materially from those anticipated. Forward-looking
statements contained in this news release are expressly qualified
by this cautionary statement. The forward-looking statements
contained in this news release are made as of the date of this news
release and the Company will update or revise publicly any of the
included forward-looking statements as expressly required by
applicable law.